Tag: PTCT

FB Nasdaq FB Facebook
Finance

Biotech Volatile Stocks: PTC Therapeutics (NASDAQ:PTCT), Agios Pharmaceuticals Inc (NASDAQ:AGIO), BioCryst Pharmaceuticals (NASDAQ:BCRX), TG Therapeutics (NASDAQ:TGTX)

PTC Therapeutics, Inc. (NASDAQ:PTCT) announced a corporate update and reported its financial results for the fourth quarter and full-year ended December 31, 2013. In April 2013, PTC Therapeutics, Inc. (NASDAQ:PTCT) initiated the confirmatory Phase 3 ACT DMD (Ataluren Confirmatory Trial in DMD) clinical trial evaluating ataluren as a potential treatment for patients with nonsense mutation Duchenne muscular dystrophy (nmDMD). PTC Therapeutics, Inc. (NASDAQ:PTCT) stock performance … Continue reading Biotech Volatile Stocks: PTC Therapeutics (NASDAQ:PTCT), Agios Pharmaceuticals Inc (NASDAQ:AGIO), BioCryst Pharmaceuticals (NASDAQ:BCRX), TG Therapeutics (NASDAQ:TGTX)

Colin Pettis
Finance

Biotech Bearish Stocks: Reliv International (NASDAQ:RELV), Ocera Therapeutics (NASDAQ:OCRX), MediciNova (NASDAQ:MNOV), PTC Therapeutics (NASDAQ:PTCT)

Registrant and three of its wholly-owned subsidiaries, Reliv, International, Inc (NASDAQ:RELV), Reliv World Corporation and SL Technology, Inc. entered into a Credit Agreement with BMO Harris Bank N.A. (the “Bank”) pursuant to which the Bank agreed to provide certain credit facilities to Registrant, including a Term Loan in the principal amount of $3,481,961 and a revolving credit facility in the amount of $5,000,000. Reliv International, … Continue reading Biotech Bearish Stocks: Reliv International (NASDAQ:RELV), Ocera Therapeutics (NASDAQ:OCRX), MediciNova (NASDAQ:MNOV), PTC Therapeutics (NASDAQ:PTCT)

Jayne Crisman
Finance

Biotech Decliners: Peregrine Pharmaceuticals (NASDAQ:PPHM), CytRx Corporation (NASDAQ:CYTR), PTC Therapeutics (NASDAQ:PTCT), Amicus Therapeutics (NASDAQ:FOLD)

Peregrine Pharmaceuticals (NASDAQ:PPHM) announced its earnings results on Friday. The company reported ($0.06) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.06). Peregrine Pharmaceuticals (NASDAQ:PPHM) stock performance was -8.05% in last session and finished the day at $2.40. Traded volume was 14.14million shares in the last session and the average volume of the stock remained 4.31million shares. The beta of the … Continue reading Biotech Decliners: Peregrine Pharmaceuticals (NASDAQ:PPHM), CytRx Corporation (NASDAQ:CYTR), PTC Therapeutics (NASDAQ:PTCT), Amicus Therapeutics (NASDAQ:FOLD)

Kristen Barton
Finance

Sizzling Stocks: PTC Therapeutics, Inc. (NASDAQ:PTCT), Frontier Communications Corporation (NASDAQ:FTR), The Michaels Companies, Inc. (NASDAQ:MIK), Southwest Gas Corporation (NYSE:SWX), China Unicom (NYSE:CHU)

PTC Therapeutics (NASDAQ:PTCT) EVP Neil Gregory Almstead sold 26,096 shares of PTC Therapeutics stock on the open market in a transaction that occurred on Wednesday, January 21st. The shares were sold at an average price of $60.26, for a total value of $1,572,544.96. PTC Therapeutics, Inc. (NASDAQ:PTCT) belongs to Healthcare sector. Its weekly performance is -3.34%. On last trading day company shares ended up $55.54. … Continue reading Sizzling Stocks: PTC Therapeutics, Inc. (NASDAQ:PTCT), Frontier Communications Corporation (NASDAQ:FTR), The Michaels Companies, Inc. (NASDAQ:MIK), Southwest Gas Corporation (NYSE:SWX), China Unicom (NYSE:CHU)

Kevin Long
Finance

Active Watch List : Johnson & Johnson (NYSE:JNJ), Applied Materials, Inc. (NASDAQ:AMAT), PTC Therapeutics, Inc. (NASDAQ:PTCT), DIRECTV (NASDAQ:DTV), Phillips 66 Partners (NYSE:PSXP)

Johnson & Johnson (NYSE:JNJ) announced a definitive agreement to acquire Alios BioPharma, Inc., a privately held clinical stage biopharmaceutical company focused on developing therapies for viral diseases, for approximately $1.75 billion in cash. The acquisition will include Alios BioPharma’s portfolio of potential therapeutics for viral infections including compound AL-8176, an orally administered antiviral therapy currently in Phase 2 studies for the treatment of infants with … Continue reading Active Watch List : Johnson & Johnson (NYSE:JNJ), Applied Materials, Inc. (NASDAQ:AMAT), PTC Therapeutics, Inc. (NASDAQ:PTCT), DIRECTV (NASDAQ:DTV), Phillips 66 Partners (NYSE:PSXP)

Chris Lewis